Pfizer (NYSE:PFE) Shares Down 1.2% – What’s Next?

Pfizer Inc. (NYSE:PFE) fell 1.2% during trading on Wednesday . The stock traded as low as $26.18 and last traded at $26.29. Approximately 31,685,855 shares changed hands during mid-day trading, a decline of 25% from the average daily volume of 42,408,969 shares. The stock had previously closed at $26.62.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s non-COVID portfolio is gaining momentum, with new product launches, acquisitions and late-stage pipeline programs intended to support growth from 2029 onward. Non-COVID products reportedly grew 5%, helping management raise its 2026 outlook while targeting approximately $9.7 billion in savings. Will Pfizer’s Non-COVID Portfolio Drive Its Next Phase of Growth?
• Positive Sentiment: Pfizer’s pipeline received a boost from positive topline Phase 3 results for LITFULO in adults and adolescents with nonsegmental vitiligo. Successful development could broaden the drug’s commercial opportunity and support the company’s post-COVID product mix. Pfizer Agreed To A $44 Million Chantix Settlement
• Positive Sentiment: Erste Group raised its 2026 Pfizer earnings estimate to $2.95 per share from $2.92, broadly in line with the approximately $2.97 analyst consensus. Pfizer Earnings Estimate Update
• Neutral Sentiment: Pfizer’s acquisitions and pipeline investments are reshaping its healthcare strategy and could improve its long-term growth profile, although the benefits are expected to emerge gradually rather than immediately. Acquisitions Reshape Pfizer’s Healthcare Strategy
• Negative Sentiment: Analysts and investors remain concerned that part of Pfizer’s improved 2026 outlook depends heavily on a product approaching patent expiration, raising questions about the durability of earnings and the company’s ability to offset future generic competition. Pfizer Raised Its 2026 Guidance
• Negative Sentiment: Pfizer agreed to pay $44 million to settle class-action claims related to Chantix safety disclosures. While modest relative to Pfizer’s size, the settlement adds to investor scrutiny of legal liabilities. Separately, Arbutus reported filing international patent lawsuits against Pfizer and BioNTech tied to lipid nanoparticle technology, creating another potential legal overhang. Pfizer Chantix Settlement

Wall Street Analyst Weigh In

Several analysts have issued reports on PFE shares. Wall Street Zen raised shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Wolfe Research reissued an “underperform” rating and issued a $26.00 price objective on shares of Pfizer in a research report on Thursday, May 14th. Guggenheim lowered their price objective on shares of Pfizer from $35.00 to $31.00 and set a “buy” rating on the stock in a research note on Friday, August 7th. CICC Research assumed coverage on shares of Pfizer in a report on Thursday, April 16th. They issued an “outperform” rating and a $33.00 target price on the stock. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Pfizer in a research note on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $28.28.

Pfizer Trading Down 1.2%

The company has a market cap of $149.84 billion, a P/E ratio of 34.59 and a beta of 0.34. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. The business has a fifty day moving average price of $25.07 and a 200-day moving average price of $26.18.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.68 by $0.09. The business had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The firm’s quarterly revenue was up 2.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, analysts forecast that Pfizer Inc. will post 2.97 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be paid a $0.43 dividend. The ex-dividend date is Friday, July 24th. This represents a $1.72 annualized dividend and a yield of 6.5%. Pfizer’s payout ratio is 226.32%.

Institutional Investors Weigh In On Pfizer

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. grew its holdings in shares of Pfizer by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock worth $13,479,520,000 after purchasing an additional 7,031,162 shares in the last quarter. BlackRock Inc. increased its holdings in Pfizer by 6.3% in the 2nd quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock valued at $12,754,464,000 after buying an additional 31,412,883 shares during the period. State Street Corp lifted its holdings in shares of Pfizer by 0.5% during the 4th quarter. State Street Corp now owns 300,445,164 shares of the biopharmaceutical company’s stock worth $7,481,085,000 after acquiring an additional 1,357,756 shares during the period. Geode Capital Management LLC boosted its position in shares of Pfizer by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 130,192,081 shares of the biopharmaceutical company’s stock worth $3,235,642,000 after acquiring an additional 1,184,728 shares in the last quarter. Finally, Morgan Stanley increased its stake in Pfizer by 19.2% in the fourth quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock valued at $2,218,929,000 after acquiring an additional 14,342,946 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.